Literature DB >> 8726012

In vitro synergy testing of macrolide-quinolone combinations against 41 clinical isolates of Legionella.

S J Martin1, S L Pendland, C Chen, P Schreckenberger, L H Danziger.   

Abstract

Combination antimicrobial therapy against Legionella species has not been well studied. Several quinolones have activity against Legionella strains, which prompted this in vitro search for a synergistic combination with the macrolides. By a checkerboard assay, erythromycin, clarithromycin, and azithromycin, each in combination with ciprofloxacin and levofloxacin, were tested for synergy against 46 isolates of Legionella. The agar dilution method was employed using buffered charcoal-yeast extract media. A final inoculum of 10(4) CFU per spot was prepared from 24-h growth of each isolate. Plates were incubated at 35 degrees C for 48 h. Synergy, partial synergy, additive effect, or indifference was observed for all combinations of antibiotics tested. There was no antagonism observed. Synergy occurred to a significantly greater extent for the clarithromycin-levofloxacin (P = 0.0001) and azithromycin-levofloxacin (P = 0.003) combinations versus erythromycin-levofloxacin. The azithromycin-ciprofloxacin combination demonstrated significantly greater synergy than did either erythromycin-ciprofloxacin (P = 0.003) or clarithromycin-ciprofloxacin (P = 0.001). The newer macrolides clarithromycin and azithromycin may be more active in combination with a fluoroquinolone than is erythromycin.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8726012      PMCID: PMC163342          DOI: 10.1128/AAC.40.6.1419

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Activity of sparfloxacin (AT-4140), PD127391 and PD131628 against Legionella spp.

Authors:  R N Jones
Journal:  J Antimicrob Chemother       Date:  1991-03       Impact factor: 5.790

2.  In vitro activity of clarithromycin (TE-031, A-67268) and 14OH-clarithromycin alone and in combination against Legionella species.

Authors:  R N Jones; M E Erwin; M S Barrett
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-11       Impact factor: 3.267

3.  Ciprofloxacin in the treatment of legionellosis in critically ill patients including those cases unresponsive to erythromycin.

Authors:  K E Unertl; F P Lenhart; H Forst; G Vogler; V Wilm; W Ehret; G Ruckdeschel
Journal:  Am J Med       Date:  1989-11-30       Impact factor: 4.965

4.  Failure of treatment of legionella pneumonia with ciprofloxacin.

Authors:  R W Kurz; W Graninger; T P Egger; H Pichler; K H Tragl
Journal:  J Antimicrob Chemother       Date:  1988-09       Impact factor: 5.790

5.  Sensitivity and resistance of Legionella pneumophila to some antibiotics and combinations of antibiotics.

Authors:  B G Moffie; R P Mouton
Journal:  J Antimicrob Chemother       Date:  1988-10       Impact factor: 5.790

6.  Unsuccessful treatment of Legionella pneumophila infection with a fluoroquinolone.

Authors:  J M Salord; P Matsiota-Bernard; F Staïkowsky; M Kirstetter; J Frottier; C Nauciel
Journal:  Clin Infect Dis       Date:  1993-09       Impact factor: 9.079

7.  Comparison of the activity of three antibiotic regimens in severe Legionnaires' disease.

Authors:  E Dournon; C Mayaud; M Wolff; B Schlemmer; D Samuel; J P Sollet; P Levasseur-Rajagopalan
Journal:  J Antimicrob Chemother       Date:  1990-10       Impact factor: 5.790

8.  Determination of the activity on Legionella of eight macrolides and related agents by comparative testing on three media.

Authors:  N Bornstein; C Roudier; J Fleurette
Journal:  J Antimicrob Chemother       Date:  1985-01       Impact factor: 5.790

9.  Antimicrobial activities of two investigational fluoroquinolones (CI-960 and E4695) against over 100 Legionella sp. isolates.

Authors:  B B Gooding; M E Erwin; M S Barrett; D M Johnson; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

10.  Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides.

Authors:  D J Hardy; D M Hensey; J M Beyer; C Vojtko; E J McDonald; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1988-11       Impact factor: 5.191

  10 in total
  7 in total

1.  High-Throughput Intracellular Antimicrobial Susceptibility Testing of Legionella pneumophila.

Authors:  Lucius Chiaraviglio; James E Kirby
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

2.  Antioxidant and antibacterial activities of Pelargonium asperum and Ormenis mixta essential oils and their synergistic antibacterial effect.

Authors:  Wessal Ouedrhiri; Mounyr Balouiri; Samira Bouhdid; El Houssaine Harki; Sandrine Moja; Hassane Greche
Journal:  Environ Sci Pollut Res Int       Date:  2017-07-22       Impact factor: 4.223

Review 3.  Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract.

Authors:  H D Langtry; H M Lamb
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

4.  Effects of Fluoroquinolones and Azithromycin on Biofilm Formation of Stenotrophomonas maltophilia.

Authors:  Aihua Wang; Qinqin Wang; Timothy Kudinha; Shunian Xiao; Chao Zhuo
Journal:  Sci Rep       Date:  2016-07-13       Impact factor: 4.379

5.  Legionella antimicrobial sensitivity testing: comparison of microbroth dilution with BCYE and LASARUS solid media.

Authors:  Edward Portal; Kirsty Sands; Artjoms Portnojs; Victoria J Chalker; Owen B Spiller
Journal:  J Antimicrob Chemother       Date:  2021-04-13       Impact factor: 5.790

Review 6.  Legionnaires' Disease: Update on Diagnosis and Treatment.

Authors:  Diego Viasus; Valeria Gaia; Carolina Manzur-Barbur; Jordi Carratalà
Journal:  Infect Dis Ther       Date:  2022-05-03

7.  The Anti-virulence Efficacy of 4-(1,3-Dimethyl-2,3-Dihydro-1H-Benzimidazol-2-yl)Phenol Against Methicillin-Resistant Staphylococcus aureus.

Authors:  Nagendran Tharmalingam; Rajamohammed Khader; Beth Burgwyn Fuchs; Eleftherios Mylonakis
Journal:  Front Microbiol       Date:  2019-07-17       Impact factor: 5.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.